X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JMKX003801 is a novel small molecule drug which is being evaluated in preclinical studies for the treatment of infection caused by Gram-negative bacteria.
Lead Product(s): JMKX003801
Therapeutic Area: Infections and Infectious Diseases Product Name: JMKX003801
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
Under the terms of the agreement, Genentech will be granted an exclusive license to develop and commercialize the JMKX002992 worldwide, and will be fully responsible for the development and commercialization costs.
Lead Product(s): JMKX002992
Therapeutic Area: Oncology Product Name: JMKX002992
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $650.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement August 18, 2022
Details:
According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.
Lead Product(s): JMKX000623
Therapeutic Area: Neurology Product Name: JMKX000623
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Pharma
Deal Size: Undisclosed Upfront Cash: $15.8 million
Deal Type: Agreement May 06, 2022
Details:
According to the agreement, Orion has the right to develop and commercialize the drug precursor in its own territory. JMKX000623 is a potent and selective Nav1.8 blocker independently developed by Jemincare.
Lead Product(s): JMKX000623
Therapeutic Area: Neurology Product Name: JMKX000623
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: $16.1 million
Deal Type: Agreement May 06, 2022
Details:
The clinical trial of JMB2002 was a single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I trial was designed to evaluate JMB2002's tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects.
Lead Product(s): JMB2002
Therapeutic Area: Infections and Infectious Diseases Product Name: JMB2002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Details:
JMB2002 can precisely occupy the key epitope of the receptor binding domain on the S1 subunit of the SARS-CoV-2 with human angiotensin-converting enzyme II binding interface, and has strong binding and blocking activities to the spike glycoproteins of mutant viruses.
Lead Product(s): JMB2002
Therapeutic Area: Infections and Infectious Diseases Product Name: JMB2002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021
Details:
Preclinical studies of JMB2002 including pharmacology and toxicity were carried out systemically. The drug metabolism, safety and efficacy were well performed. In early studies, it was found that JMB2002 could effectively neutralize live virus infection of Vero E6 cells.
Lead Product(s): JMB-2002
Therapeutic Area: Infections and Infectious Diseases Product Name: JMB-2002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
